Our tests are based on samples taken in painless manner by fine needle aspiration of the subcutaneous abdominal adipose tissue and an additional blood draw. The tests provide the attending physician with patient-individual recommendations for therapy-planning and theapy-control.
The DiaSquare test is designed to provide a personalised and optimal recommendation on oral antidiabetic treatment for type-2_diabetes (T2D) within a few days.
The marker is used as a single test either for newly diagnosed type-2-diabetics or for therapy adjustment with already diagnosed type-2-diabetics
Existing methods of therapy-finding for a newly diagnosed T2D patient are set out in the National Guidelines. They provide for a systematic trial-and-error of (oral) antidiabetics. The patient is given a specific drug over a period of up to six months and at the end of the period, the blood-glucose level is measured. If there is sufficient improvement in the blood glucose level, the medication is maintained; otherwise, other drugs are sequentially tried out until a sufficient reduction of blood-glucose levels can be achieved.
This method shows two fundamental disadvantages.
On the one hand, the time needed for finding effective therapy can be very long. It can take up to 24 or even 36 months. However, as T2D is a progressive chronic disease, the health of the patient continues to deteriorate during this phase. In particular, there is a rapid increase in the likelihood that, as long as no effective medication is found, comorbidities develop which may have severe adverse effects on the patient; such as foot amputations, kidney failure, impairment of vision, heart-attacks and others.
On the other hand, this procedure bears the risk to stop short of finding an optimal therapy for the patient. The process of finding a therapy will be discontinued as soon as a drug shows at least a certain degree of improvement in the blood glucose value. No doctor can risk to discard a drug that at least shows some positive effect, just for the hope to find a potentially more effective drug by continuing the trial-and-error process.
The DiaSquare test solves both of the above problems with the existing forms of therapy-finding. By providing recommendations for certain groups of drugs for patients based on their gene profile, oral antidiabetic therapy is personalised from the very beginning.
The DiaCon-test is designed to provide continuous monitoring and adaptation of oral antidiabetic therapy in patients with type-2-diabetes (T2D).More Info
The existing methods of therapy control are based on the measuring blood glucose levels. However, the diabetic dynamics of the metabolism are not recorded and cannot be with the existing test procedures. Yet, simply treating symptomatically for blood-glucose levels will not suffice for a long-term success in treatment; this needs instead a treatment addressing the causal metabolic dynamics that have led to T2D.
Adjustments in oral antidiabetic therapy of T2D patients are closely related to the methods of finding therapy as defined in the national guidelines. These guidelines provide for a systematic trial-and-error-process of testing out oral antidiabetics on a patient. This trial-and error-process is standard for therapy-adaptation as well.
This trial-and-error-method shows two fundamental disadvantages.
On the one hand, the time needed for finding an effective adjusted therapy can be very long. It can take up to 24 or even 36 months. However, as T2D is a progressive chronic disease, the health of the patient continues to deteriorate during this phase. In particular, there is a rapid increase in the likelihood that, as long as no effective medication is found, comorbidities develop which may have severe adverse effects on the patient; such as foot amputations, kidney failure, impairment of vision, heart-attacks and others.
On the other hand, this procedure bears the risk to stop short of finding an optimal adjusted therapy for the patient. The process of finding a therapy will be discontinued as soon as a new drug shows again at least a certain degree of improvement in the blood glucose level. No doctor can risk to discard a drug that at least shows some positive effect, just for the hope to find a potentially more effective drug by continuing the trial-and-error process.
The DiaCon-test provides better and in-depth insights with therapy-control for the treating physician. In particular, the tests shows whether a particular oral antidiabetic positively regulates the metabolic dynamics that are associated with insulin resistance or whether adapting oral treatment will show better results in the long run.
DiaCon offers for therapy-adjustment all the benefits that DiaSquare test offers for planning the initial therapy.
The test is designed to provide the attending physician with information on the status of the patient's T2D-related metabolic dynamics in the course of therapy control and potential therapy-adjustment.
DiaPro is an early diagnostic test for the identification of pre-diabetics and for so far undiagnosed Type-2-diabetics. DiaPro allows to already diagnose patients when the diabetic dynamics in their metabolism first set in, even if the blood glucose levels do not yet show any significant changes.Mehr Info
Today, the prediction of pre-diabetics is done based on testing for HbA1c. This marker is not well apt for early-diagnosis and prognostics as it renders unspecific results. While HbA1c only responds to elevated blood-glucose levels covering a period of three months prior to testing, the metabolic dynamics that lead to diabetes set in years earlier, before any significant changes in blood-glucose levels can be detected. Therefore, HbA1c and other markers only respond when pre-diabetes is already well advanced and close to turning into manifest type-2-diabetes (T2D).
To avoid T2D, however, effective prevention should set in much earlier than allowed for by the HbA1c measurement. Furthermore, prevention should be based on information on the metabolic dynamics and insulin resistance leading to T2D and not on simply stating elevated blood-glucose levels.
DiaPro test allows an identification of a developing T2D years earlier than existing tests. Therefore, intervention can be planned on a less aggressive and intervening scale.
Used for repetitive controlling of pre-diabetes intervention with a patient, DiaPro can monitor whether and to what extent a preventive therapy is effective and to what extent it should be supported by medication.
The test is designed to allow the attending physician a basic classification of the patient into specific groups which are associated with pre-diabetes risk profiles and for which therapy-recommendations can be given.
DiaBar is a decision-making test. It can be used to determine whether a patient suffering from type-2-diabetes (T2D) could experience a remission of his T2D from bariatric surgery and whether this remission would be lasting.More Info
Basically, bariatric surgery, such as gastric bypass, sleeve gastrectomy, adjustable gastric band, and biliopancreatic diversion with duodenal switch, can lead to a remission of an existing T2D. This remission, if it occurs, sets in very quickly, within days to weeks, after the intervention.
However, remission does not occur in every patient, and in a large number of patients no improvement of the T2D at all is reached by bariatric surgery. In addition, the sustainability of the remission is not assured for those patients who initially benefit from a bariatric surgery. Many of these patients experience a relapse of their T2D in a short time.
Bariatric surgery is a very severe intervention affecting a healthy organ. It impairs the functioning of the organ leading to severe comorbidities, such as digestive and metabolic disorders, and the lifetime supplementation of minerals and vitamins.
Out of these comorbidities arises a fundamental problems in decision-making: If a patient benefits from a bariatric intervention seeing a long-term remission of his T2D, this undoubtedly outweighs the disadvantages of ensuing comorbidities. However, if a patient experiences only a short-term remission, or none at all, these comorbidities represent a considerable and unacceptable burden. In this case, the patient would not only continue to suffer from T2D, but would also suffer additional restrictions from the comorbidities. For this reason, the use of bariatric surgery as an innovative treatment option for T2D raises significant concerns. Today, there is no reliable method of decision-making for or against a bariatric surgery with any individual patient.
DiaBar offers just this basis for decision-making. It will give an indication as to whether a particular patient could profit from bariatric surgery with regard to his T2D and whether a remission will be lasting.